New Scientist is for sale

Science and medical publishing giant linkurl:Reed Elsevier;https://www.the-scientist.com/blog/display/53577/ has announced that is putting Reed Business Information (RBI), the largest business-to-business publisher in the US, up on the auction block. The sale will include __New Scientist__. Although Reed Elsevier also owns __The Lancet__ and __Cell__, among other journals, as well as science and medical textbooks, none of those titles are for sale. RBI also publishes __Variety__ and other consu

By | February 21, 2008

Science and medical publishing giant linkurl:Reed Elsevier;https://www.the-scientist.com/blog/display/53577/ has announced that is putting Reed Business Information (RBI), the largest business-to-business publisher in the US, up on the auction block. The sale will include __New Scientist__. Although Reed Elsevier also owns __The Lancet__ and __Cell__, among other journals, as well as science and medical textbooks, none of those titles are for sale. RBI also publishes __Variety__ and other consumer-oriented magazines and trade publications. According to linkurl:analysts,;http://www.thisislondon.co.uk/standard/article-23440523-details/Reed+Elsevier+plans+%C2%A32.5bn+mags+sell-off/article.do the sale of RBI could fetch more than $2.5 billion. Reed Elsevier CEO Sir Crispin Davis, said on the company's linkurl:website;http://www.reed-elsevier.com/index.cfm?articleid=2199 that "today we have announced a further major step with the planned divestment of Reed Business Information ("RBI"). RBI is a well-managed high quality business as evidenced by the success of its online growth and the control of costs. Its advertising revenue model and the inherent cyclicality fit less well however with the subscription-based information and workflow solutions focus of Reed Elsevier's strategy." The announcement to sell RBI came today (Feb 21) among a broader cost-saving plan and news that Reed Elsevier has purchased ChoicePoint Inc., the largest US provider of information to the insurance industry, for about $4.1 billion.

Popular Now

  1. Man Receives First In Vivo Gene-Editing Therapy
  2. Researchers Build a Cancer Immunotherapy Without Immune Cells
  3. Immune Checkpoint Found Lacking in Type 1 Diabetes
  4. Research Links Gut Health to Neurodegeneration
    The Nutshell Research Links Gut Health to Neurodegeneration

    Rodent studies presented at the Society for Neuroscience meeting this week tie pathologies in the gastrointestinal tract or microbiome composition with Parkinson’s and Alzheimer’s diseases.

RayBiotech